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The current paradigm of pancreatic neoplastic transformation proposes an initial step whereby acinar cells convert into
acinar-to-ductal metaplasias, followed by progression of these lesions into neoplasias under sustained oncogenic activity
and inflammation. Understanding themolecular mechanisms driving these processes is crucial to the early diagnostic and
prevention of pancreatic cancer. Emerging evidence indicates that transcription factors that control exocrine pancreatic
development could have either, protective or facilitating roles in the formation of preneoplasias and neoplasias in the
pancreas.We previously identified that the homeodomain transcription factor Prox1 is a novel regulator ofmouse exocrine
pancreasdevelopment.Herewe investigatedwhetherProx1 functionparticipates inearlyneoplastic transformationusing in
vivo, in vitro and in silico approaches. We found that Prox1 expression is transiently re-activated in acinar cells undergoing
dedifferentiation and acinar-to-ductal metaplastic conversion. In contrast, Prox1 expression is largely absent in neoplasias
and tumors in the pancreas of mice and humans. We also uncovered that Prox1-heterozygosis markedly increases the
formation of acinar-to-ductal-metaplasias and early neoplasias, and enhances features associated with inflammation, in
mouse pancreatic tissues expressing oncogenic Kras. Furthermore, we discovered that Prox1-heterozygosis increases
tissue damage and delays recovery from inflammation in pancreata of mice injected with caerulein. These results are the
first demonstration that Prox1 activity protects pancreatic cells from acute tissue damage and early neoplastic
transformation. Additional data in our study indicate that this novel role of Prox1 involves suppression of pathways
associated with inflammatory responses and cell invasiveness.
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Invasive pancreatic ductal adenocarcinoma (PDAC) is among the
least curable and most lethal solid malignancies, with patients having
a survival rate of less than 4% [1]. PDAC arises from distinct
morphologic precursor lesions, of which pancreatic intraepithelial
neoplasias (PanINs) are best characterized. PanINs are microscopic
papillary or flat, noninvasive ductal intraepithelial neoplasms that,
depending on the extent of cytologic atypia, are classified as PanIN-1
(low-grade dysplasia), PanIN-2 (moderate dysplasia), and PanIN-3
(high-grade dysplasia) lesions [2]. PDAC can also originate from
other less well-characterized premalignant lesions, including intra-
ductal papillary mucinous neoplasms (IPMN) and mucinous cystic
neoplasms (MCN) [3].
Recent lineage-tracing studies established that pancreatic acinar
cells could give rise to PanINs when exposed to oncogenic Kras
activity and inflammation [4]. Acinar cells, the most abundant cell
type in the pancreas, are involved in the production of numerous
zymogens necessary for nutrient digestion. Adult acinar cells are
relatively plastic, and under certain pathologic conditions they
dedifferentiate into a progenitor/duct-like lesion called acinar-to-
ductal metaplasia (ADM) [4–6]. ADMs are prevalent in individuals
with pancreatitis or pancreatic cancer, and it has been proposed that
under sustained oncogene stimulation or chronic inflammation these
lesions give rise to PanINs [4]. The formation of ADMs involves
re-expression of transcription factors (TFs) and components of
signaling pathways that normally function in pancreatic progenitors
[7–11]. The role of these factors in ADMs is not fully established, but
they probably contribute to erase an acinar-differentiation program
and to confer plasticity to these structures [7,9,11,12].
Our previous studies identified expression of the homeodomain TF
Prox1 in multipotent progenitors, islet cells, and ductal cells in the
pancreas of mouse embryos and in most epithelial cells in the pancreas
of adult mice, except in acinar cells [13,14]. We also reported that
pancreas-specific ablation of Prox1 causes premature acinar cell
differentiation [13] and defective ductal morphogenesis at embryonic
stages, and promotes acinar cell apoptosis and mild chronic
inflammation at postnatal stages [14]. The expression of Prox1 in
multipotent progenitors and ductal cells of the pancreas overlaps with
that of the One Cut Domain TF Hnf6 [15,16]. Moreover, Prox1 and
Hnf6 activities are similarly required for exocrine pancreas develop-
ment and some results indicate that in these tissues Hnf6 could
function upstream of Prox1 [16]. Interestingly, 2 recent studies
showed that Hnf6 expression is upregulated in ADMs of mice and
humans [8,10]. These results indicate that Prox1 could be induced
together with Hnf6 in ADMs. Moreover, Prox1 activity could play a
protective role in neoplastic transformation in the pancreas because a
study by Takahashi et al [17] showed that Prox1 ectopic expression
suppresses the growth of pancreatic cancer cells.
Here we analyzed the expression of Prox1 in ADMs, neoplasias,
and tumors in the pancreas of mice and humans using immuno-
staining methods. We also investigated whether Prox1 activity
participates in ADM formation using acinar cultures. In addition, we
examined the effects of reduced Prox1 activity in oncogene-induced
pancreatic transformation using mouse models. Finally, we used
comparative gene expression analyses to investigate how Prox1
activity reduces the malignant potential of transformed pancreatic
cells. Our study underscored a novel protective role of Prox1 against
tissue damage and oncogenic transformation in the mammalian
pancreas.Materials and Methods
Mouse Procedures
Generation of Prox1loxP/+ [18], Ptf1a+/cre [19], KrasG12D [20] and
Pdx1-Cre [21] mice has been described previously. Mice were
maintained in a mixed C57/NMRI genetic background. Mice were
treated according to the criteria outlined in the Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health. All
animal experiments were reviewed and approved by the St Jude Animal
Care and Use Committee.
Human Tissues
Seven tissue microarrays (TMAs) (total 126 cases) were obtained
from the Johns Hopkins Hospital and were stained for PROX1.
Additional paraffin sections of human tissues were obtained from the
Vanderbilt University Medical Center.
Cell Lines
Capan1, HepG2, MiaPaCa-2, Panc-1 and βTC were obtained
from the ATCC and cultured at 37°C, 5% CO2, and 20% O2
according to the ATCC guidelines.
Cell Viability Analysis
Capan1 cells maintained in the logarithmic phase of growth were
trypsinized, counted, and plated at 500 cells/well in 96-well plates in a
total volume of 100 μl of complete medium. Viability was assessed
starting on the same day and for 7more days using theCell Titer Aqueous
Viability assay (Promega) following the manufacturer’s instructions.
Acinar Cell Cultures
Primary acinar cells were isolated and cultured as described
previously [22]. For RNA isolation, collagen disks were treated with
0.2 mg/mL collagenase P for 10 min, centrifuged at 2000 rpm, and
washed twice with HBSS. The cell pellet was resuspended in 350 μL
RLT buffer, and total RNA was extracted by using the Qiagen
RNeasy Mini Kit. Collagen from BD Biosciences was used to culture
acini from KC and KCH mice, and collagen from Life Sciences was
used to culture acini from Ptf1a+/cre mice.
To measure proliferation in ADMs, collagen disks were fixed in 4%
PFA for 5 h at 4°C, and embedded in OCT. Thick sections (12 μm)
were stained for Ki67 and E-cadherin, and counterstained with DAPI.
Ki67+/DAPI+/Ecad+ cells were quantified using ImageJ suite and the
cell counter plugin, counting at least 10microscope fields per genotype.
Immunohistochemical Analysis
Tissue processing and immunostaining were done as described
previously [23]. All primary and secondary antibodies used in this
study are listed in Supplemental Table 1. Images were obtained with a
Zeiss Axioskop 2 microscope, or with a confocal/Multiphoton
laser-scanning Zeiss LSM 510 META microscope. Immunohisto-
chemically stained slides were further scanned with an Aperio slide
scanner (Leica). To measure CD45+ and F4/80+ cells, the algorithm
“IHCnuclear staining”was applied on the scanned slides and in the area
covering the whole pancreas, excluding the lymph nodes. αSMA + foci
were measured using ImageJ on low magnification images exported
from Aperio.
Western Blot Analysis
Whole pancreata from 3-month-old KC and KCH pancreata were
processed as described in [14]. Antibodies used for WB are described
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images was performed using imageJ software.
Morphometric Analysis and Lesion Scoring
PanIN scoring was performed as previously described [24], with
modifications. For each genotype and time point, at least 3 mice of
identical genotype were used and pancreas was completely sectioned. For
each pancreas, 5 to 7 representative sets consisting of 12 slides each were
obtained (each set was separated by 200 μm). After H&E staining of a
single section of each set and photomicrography of the whole area (10 to
20 pictures per section), the total area of the section was determined by
using the image J software (NIH, http://imagej.nih.gov/ij/). PanINs
were counted in each representative section and scored according to their
histological characteristics [2]. To measure the number and size of
acinar-derived cystic structures (ADMs), the cultures were photographed
daily by using the EVOS FL Auto Cell Imaging microscope, and
Z-stacks from each culture were obtained. Image J was used to count the
total area of each field photographed, the number of ADMs, and the area
of each ADM in selected representative images.
RNA Extraction and Quantitative RT-PCR
RNA isolation and cDNA synthesis was performed as previously
described [23]. The mRNA levels of each transcript were normalized
against the expression of 18sRNA, using the ΔΔct method. Ptf1a+/cre
animals were used as controls. All primers used in the study are listed
in Supplemental Table 2.
Retroviral Preparation and Capan1 Transduction
The open reading frame (ORF) of human PROX1 cDNA was
cloned into an MSCV-SV40-PuroR plasmid, and retroviral particles
were prepared by tripartite transfection of 293T cells, followed by
harvest of viral particles. 293T cells were transfected with either
MSCV-Prox1-PuroR or empty MSCV-SV40-PuroR vector, and 2
plasmids carrying the viral packaging proteins, by using the CaCl2
method. The supernatant containing viral particles was harvested 24
hours later, filtered through a 0.45-μm gauze filter, and immediately
used for transduction. Capan1 cells were transduced with ampho-
tropic retroviruses carrying either an MSCV-SV40-PuroR or an
MSCV-Prox1-PuroR. Two days post-transduction the cells were
incubated with 0.5 mg/mL puromycin and selected for 4 days. RNA
was isolated from 3 independent transductions with each construct
and puromycin selection, using Trizol and the PureLink RNA Mini
kit (Life Technologies).
Soft Agar Clonogenic Assay
Capan1 wild type, puro or Prox1-puro cells were mixed in 0.4%
Nobleagar (in RPMI supplemented with 10% fetal bovine serum)
and plated at 2,500 cells/well onto 6-well plates containing a
solidified bottom layer (0.6% Noble agar in the same growth
medium). After 21 days, colonies were stained with 0.05% crystal
violet and photographed using EVOS. For each experiment, ten
low-powered fields (4×) were counted per well.
Immunofluorescence of Cultured Cells
Capan1 cells grown on 4-well chamber slides (Millipore) were fixed
with 4% PFA for 15 min at RT, permeabilized and washed with 0.1
% Triton X-100 in PBS, and incubated with primary antibodies and
rhodamine-phalloidin in PBS, 3% BSA, 0.1% Triton X-100 for 1 h
at RT. Cells were washed with 0.1% Triton X-100, incubated withsecondary antibodies in PBS, 3% BSA, 0.1% Triton X-100 for 30
min at RT. Slides were covered with Prolong anti-fade medium plus
DAPI and photographed with a Leica DM 2500 confocal microscope.
Microarray Gene Expression Analysis
Total RNA (100 ng) extracted either from Capan1-transduced cells
(3 biological replicates of each condition) or pancreata from postnatal
day 7 mice was converted into biotin-labeled cRNA (Affymetrix
3’IVT Express Kit, Affymetrix, Inc.) and hybridized to a Human
PrimeView GeneChip or to a mouse HT MG-430 PM GeneChip
array (Affymetrix, Inc.), respectively. Probe signals from arrays were
normalized and transformed into log2 transcript expression values by
using the Robust Multi-array Average algorithm [25] (Partek
Genomics Suite v6.6). Functional enrichment analysis of gene lists
was performed by using the DAVID bioinformatics databases [26]
(http://david.abcc.ncifcrf.gov/). Microarray data have been deposited
in Gene Expression Omnibus under the accession number
GSE58547. FDR was b0.05 except for the genes upregulated in
the Capan1-PROX1 analysis where FDR was b0.1.
Caerulein-Induced Pancreatitis
For chemically induced acute pancreatitis, 6- to 8-week-oldmice (body
weight 20–25 mg) were injected with caerulein (Sigma) as described
previously [5], with the followingmodifications. Eachmouse was injected
with 72 μg caerulein per kilogram of body weight (10 mg/mL solution)
per injection and in total received 8-hourly injections daily for 2
consecutive days. Mice were fasted overnight before the first injection
and were returned to the normal feeding schedule after the last injection
(d0). For the control experiment, mice of each genotype were injected
with the same volume of saline, following the same feeding and
injection scheme. Tissues were dissected 7 days post-injections and
processed for histologic analysis. Tomeasure serum amylase, 8-week old
mice were injected with a single dose of 72 μg/kg body weight of
caerulein. After 3 h, retro-orbital blood was collected and submitted to
the St. Jude core Pathology lab.
Treatment With 5Aza-dC and TSA
Pancreatic cancer cell lines Capan1 and MiaPaCa2 were treated
with 5Aza-dC (Sigma) and TSA (Sigma) as previously described [27].
Cells were exposed continuously to 5Aza-dC (1 μM) for 4 days or to
TSA (1 μM) for 24 h. Mock-treated cells were cultured with the
equivalent volume of medium, with the addition of equal volume of
50% acetic acid in single-distilled H2O (diluent for 5Aza-dC) or
DMSO (diluent for TSA). Cells were harvested at indicated time
points, and RNA was extracted as described above.
Prox1 Meta-Analysis
Publically available microarray data from human pancreatic tumors
was downloaded from the Gene expression Omnibus (GEO
accessions: GSE39751 and GSE28735). The data was controlled
for quality using PCA and clinical meta-data to eliminate outliers in
Partek Genomics Suite 6.6 (St. Louis MO USA). The highest
expressed Prox1 probeset was extracted, examined and plotted with
respect to age, gender and other clinical features in STATA/MP11.2
(College Station TX USA).
Statistical Analyses
All statistical analyses were performed by using Microsoft Office
Excel and the two-tailed t-test. For all bar graphs, data are presented as
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microarray analysis, differentially expressed transcripts were identified
by using the local pooled error (LPE) t-test [28] and the false
discovery rate was estimated as described previously [29].
Study Approval
The Johns Hopkins institutional review board (Department of
Health and Human Services waiver 4) exempted the TMA analysis of
human samples, as it was delinked from human subject identifiers and
generated by using archival material from tissues obtained as standard
of care. Additional human tissues were obtained with approval from
the Vanderbilt University Medical Center IRB.
Results
Prox1 is Expressed in ADMs but not in PanINs and PDAC of
Mice and Humans
We investigated the expression of Prox1 in ADMs using
immunostaining methods and pancreata of 2 different mouse models:
wild-type mice injected with caerulein, and LSL-KrasG12D;Ptf1a+/cre
mice (hereafter named KC mice). In the first model, the
cholecystokinin analogue caerulein was used to induce mild
edematous pancreatitis and extensive ADM formation [30]. In the
second model, an oncogenic version of Kras (KrasG12D) was expressed
in the pancreas to induce the formation of preneoplasias (including
ADMs), PanINs and PDAC, through a disease process that is very
similar to that in humans [20,31]. Similar to our published results
[13], we detected Prox1 expression in ductal cells and centroacinar
cells but not in acinar cells in pancreata of both, caerulein-injected
wild-type mice and KC mice (Figure 1A and data not shown). Also,
we observed moderate-to-low Prox1 expression in tubular structures
resembling ADMs in pancreata of wild-type mice injected with
caerulein (Figure 1B). Likewise, we detected Prox1 expression in
ductal lesions that occasionally expressed the acinar marker amylase
(Figure 1C) in pancreata of KC mice. These results demonstrate that
Prox1 expression is induced in epithelial lesions resembling ADMs in
murine pancreatic tissues exposed to acute inflammation or
oncogenic stress.
Immunostaining results also showed that PanIN lesions of KC
mice that were labeled with the specific marker Claudin-18 [23]
lacked Prox1 expression, except in those areas that retained normal
cuboidal or flat ductal morphology and were Claudin-18 negative
(Figure 1D). In contrast, PanINs of KC mice strongly expressed Sox9
and Hnf1β (Figure 1E), 2 TFs that normally co-localize with Prox1 in
multipotent progenitors and ductal cells in the pancreas (Supple-
mental Figure 1). Moreover, in agreement with published data [8,10],
we detected Hnf6 expression in early PanINs but not in the more
advanced forms of these lesions (data not shown). Immunostaining
results also uncovered lack of Prox1 expression in the epithelium of a
less frequent neoplasia (IPMN; Figure 1F) or in PDAC specimens
(Figure 1G) of KC mice. In contrast, Sox9 and Hnf1β were broadly
expressed in IPMNs (Figure 1F) and in most PDAC specimens
(Figure 1G) of KC mice. Therefore, we uncovered that Prox1
expression is upregulated in both regenerative lesions (Figure 1B) and
epithelial structures resembling ADMs (Figure 1C), but is not
maintained in neoplasias or tumors (Figure 1, E–G), in mouse
pancreatic tissues expressing KrasG12D.
We also analyzed the expression of PROX1 in neoplasias and
tumors of humans using immunostaining methods. Similar to mice,PROX1 proteins were absent in human PanIN lesions but showed
normal distribution in the adjacent islets (Figure 1H). Immunostain-
ing of tissue microarrays containing approximately 120 individual
human pancreatic tumors showed absence of PROX1 expression in
more than 90% of the examined specimens (Figure 1I and data not
shown). In contrast, the normal-looking ducts, immune cells, and
islets surrounding those tumors were positive for PROX1
(Figure 1H). Similar to the previous immunostaining results,
screening of the human PDAC cell lines Capan1, Panc1, and
MiaPaCa2 by quantitative RT-PCR (qRT-PCR) showed very low or
no expression of PROX1 transcripts (Figure 1J and data not shown).
On the other hand, treatment of Capan1 and MiaPaCa2 cells with
the demethylating agent 5-aza-2’ deoxycytidine or the histone
deacetylase inhibitor trichostatin (Figure 1K) increased PROX1
transcript levels considerably. These results indicate that epigenetic
mechanisms contribute to silence PROX1 expression in pancreatic
tumor cells.
Prox1 Heterozygosis Enhances ADM Formation Induced by
Oncogenic Kras
Published studies showed that ADM formation requires the
activities of Sox9 and Hnf6 [7,8]. Since Prox1 could be part of the
same regulatory network involving Sox9 and Hnf6 activities in the
pancreas, we investigated whether Prox1 activity plays a role in ADM
formation by using a published ex-vivo culture system [22] involving
acinar dedifferentiation, cyst formation, loss of acinar markers (e.g.,
amylase), and induction of cytokeratin-19 (CK-19) and other ductal
markers [32]. We focused this and the subsequent analyses on testing
the effects of Prox1-haploinsufficiency and not complete lack of
Prox1 activity, because full Prox1 ablation in murine pancreatic
progenitors causes extensive loss of acinar tissue and mild chronic
inflammation [14]. In contrast, mice carrying Prox1 heterozygosis in
the pancreas (Ptf1a+/cre;Prox1loxP/+ mice, hereafter designated Prox1Δ/+)
have intact acinar tissue and do not show any obvious pancreas
abnormalities (Supplemental Figure 2).
We harvested the acini from wild-type mice, cultured these tissues
for 5 days in three-dimensional collagen gels in the presence of the
ADM inducer Transforming Growth Factor alpha (TGFα), and
analyzed the resulting cysts by immunostaining. At day 0 of culture,
all acinar cells strongly expressed amylase but were devoid of CK-19
expression (Supplemental Figure 3A). Also at day 0, most acinar cells
were negative for Sox9 or Prox1 expression although a few cells
displayed very low levels of these proteins (Supplemental Figure 3A).
After 5 days of culture the resulting cysts lost amylase expression and
became immunopositive for CK19, Sox9 and Prox1 (Supplemental
Figure 3B). These results show that Prox1 expression is activated in
ADMs formed in vitro. We also cultured the acini from Ptf1a+/cre
mice and Prox1Δ/+ mice for 5 days in the presence of TGFα and
found that the size and number of cysts formed in both genotypes
were similar (Supplemental Figure 3C). Thus, we conclude that
Prox1 heterozygosis does not affect the ex-vivo formation of ADMs.
Since we found that Prox1 is expressed in ADMs of KC pancreata
(Figure 1C), we investigated whether Prox1 haploinsufficiency affects
ADM formation in the context of oncogenic Kras using acini
dissected from KCmice and KCHmice. KCHmice (or LSL-KrasG12D;
Ptf1a+/cre;Prox1loxP/+ mice) carry both KrasG12D expression and
ablation of 1 Prox1 allele in the pancreas. As seen for acini from
wild-type mice (Supplemental Figure 3), acini from both KC and
KCH mice that were exposed for 3 days to TGFα produced cysts
Figure 1. Prox1 is expressed in metaplasias, and is largely undetected in neoplasias and tumors, in murine and human pancreata.A: Prox1
expression is detected in ductal (arrow) and centroacinar cells (arrowhead), but not in acinar cells (yellow arrowhead), in pancreata of
wild-type mice.B: Prox1 is expressed in tubular structures (yellow arrows), ducts (white arrow) and centroacinar cells (white arrowhead),
in the pancreas of wild-type mice injected with caerulein (yellow arrowhead indicates an acinus).C: ADMs express Prox1 in the pancreas
of KC mice (arrow and inset).D: Immunostaining for Prox1 and the PanIN-specific tight junction protein Claudin-18 shows near or total
absence of Prox1 in PanIN epithelia (arrowhead) of a KC pancreatic specimen. Ducts and PanIN areas retaining flat normal-appearing
morphology express Prox1 (arrows).E: PanIN-1 areas displaying abundant cytoplasm lack nuclear Prox1 expression (arrows, left) but
express Sox9 (arrows, middle) and Hnf1β (arrows, right) in KC pancreata. Left panel: Blue arrowheads show Prox1+ cells in PanIN areas
displaying normal duct morphology; blue arrowhead indicates a lymphatic vessel. Middle panel: arrowhead indicates a Sox9+ acinus. isl,
islet; ac, acinus.F: Mouse IPMNs display moderate to high expression of Sox9 (arrow, middle) and Hnf1β (arrow, right) and lack Prox1
expression (arrows, left). Arrowhead shows an area of very low Sox9 expression.G: Primary PDAC specimens of KC mice express Sox9
(arrow, middle) and Hnf1β (arrow, right) but not Prox1 (arrow, left).H: Adjacent human pancreatic sections demonstrate PROX1
expression in islet cells (arrow) but not in the CK19-positive PanIN epithelium (arrowhead).I: Human PDAC specimens in a tissue
microarray show PROX1 expression in normal ducts (black arrows) and immune cells (red arrows). In contrast, except for a few
specimens (bottom, right), the glandular epithelium (arrowheads) in most tumors is negative for PROX1.J: Quantitative RT-PCR analysis
comparing the relative abundance of PROX1 transcripts in pancreatic cancer cell lines (Capan1 and MiaPaCa2), insulinoma-derived βTC
cells, and the hepatocellular carcinoma cell line HepG2.K: Quantitative RT-PCR results show up-regulation of PROX1 in Capan1 and
MIAPaCa-2 cells treated with 5-aza-dC. Trichostatin A (TSA) treatment also increases PROX1 expression in Capan1 cells. Expression of
CLDN5 and SOX15, 2 genes that are hypermethylated in pancreatic cancer cell lines [50], is also induced in Capan1 and MiaPaca-2 cells
post-5-aza-dC treatment.Error bars represent+SEMvalues (n=3). *Pb0.05, **Pb0.01 and ***Pb0.001. Scale bars: 25μm (A-D), 50μm (E-I).
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(Figure 2A and data not shown). Remarkably, we found that the cysts
from KCH mice were larger (Figure 2, B and C), expressed
substantially more Cldn18 (Figure 2D), were more abundant
(Figure 2E), and had higher proliferation rates (Figure 2F), than the
cysts from KC mice. These results demonstrate that Prox1
heterozygosis markedly increases the in vitro formation of ADMs in
the context of oncogenic Kras.
Prox1 Heterozygosis Accelerates the Formation of Early
Neoplasias, but not Tumor Incidence, in KC Mice
The previous ADM in vitro results suggested that Prox1
heterozygosis could affect the entire neoplastic process induced by
KrasG12D. To investigate this possibility, we dissected the pancreata
of KC and KCH mice at various time points and processed these
tissues for histologic and immunostaining analyses. We first analyzed
specimens dissected at 1 month because at this age most KC mice areexpected to develop numerous preneoplasias and a few early
neoplasias (i.e., PanIN-1A) in the pancreas [20]. We found that the
areas of desmoplasia encompassing duct-like epithelial structures
surrounded by αSMA-positive mesenchymal cells (Figure 3A) were
more abundant in KCH pancreata than in KC pancreata (Figure 3B)
at 1 month of age. On the other hand, the immune infiltrates
containingmacrophages (F480+ cells) and total leukocytes (CD45+ cells)
(Figure 3A) were no different between both genotypes at that age
(Figure 3B). We also analyzed the pancreata of a 2-month old mouse
cohort and found that most KC pancreatic specimens exhibited an
enlarged but still scattered desmoplastic stroma enclosing some
low-grade PanINs (Figure 3C). In contrast, the areas of desmoplasia
were noticeably larger and both the interstitial edema and fibrosis
were more prominent in KCH pancreata compared to KC pancreata
(Figure 3C) at this age. Also, quantitative results revealed that
PanIN-1A, PanIN-1B, and PanIN-2 lesions were significantly more
abundant (Figure 3D) in KCH pancreata than in KC pancreata at 2
Figure 2. Prox1 heterozygosis affects the formation of ADMs in the context of oncogenic Kras activity.A: Day 0, Acinar cells (arrowheads)
from KC pancreata express amylase, but no CK19 or Prox1, at day 0 of culture (arrows indicate CK19+/Prox1+ centroacinar cells). Day 3,
KC acini cultured for 3 days with TGFα form cysts (arrows) that are negative for amylase and positive for CK19 and Prox1.B, C: Prox1
heterozygosis increases the size of KrasG12D-expressing acinar-derived cysts after 3 days of culture with TGFα.E: Quantitative PCR results
show higher expression of Cldn18 transcripts in KCH versus KC acinar cultures treated for 3 days with TGFα. Error bars represent + SEM
values (n=3-4 individual specimens per time point).E, F: Prox1 heterozygosis increases the number and proliferation rate of Kras-
G12D-expressing acinar-derived cysts cultured for 3 days with TGFα.*Pb0.05, **Pb0.01 and *** Pb0.001.
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cohort of KC and KCH mice that were generated using a different
Cre parental strain (Pdx1-Cre, Figure 3F) [21]. Altogether, these data
demonstrate that Prox1-heterozygosis accelerates early neoplastic
transformation induced by KrasG12D in mouse pancreata.
We also compared the incidence of pancreatic tumors in 2 cohorts
of KC and KCH mice (n=12 in each group) that were euthanized at
13–15 months of age (except for 1 KCH mouse that was found
moribund at 7 months). We uncovered that 3 mice in the KCH
group developed an IPMN lesion whereas only 1 mouse in the KC
group displayed a similar neoplasia (Figure 4A, Supplemental Table 3).
These results corroborate that Prox1 heterozygosis accelerates the
formation of KrasG12D-induced neoplasias. On the other hand, we
found that each of 4 KC mice and 4 KCH mice developed pancreatic
tumors surrounded by high-grade PanIN-3 lesions (Supplemental
Table 3 and data not shown). Histologic and immunostaining analyses
of the tumors identified 2 nonmetastatic PDACs in theKC group and 3
PDACs (2 nonmetastatic and 1 metastatic) in the KCH group
(Figure 4B). In addition, a longitudinal study performed in a separate
cohort of KC and KCH mice (n=16 in each group) showed no
differences in survival in both genotypes (Figure 4C). Thus, Prox1
haploinsufficiency does not affect pancreatic tumor incidence in mice.
We hypothesize that once specific tumor suppressors are inactivated or
certain oncogenic mutations are acquired, Prox1 downregulation
becomes irrelevant for the transformation process.Prox1 Heterozygosis Sensitizes the Pancreas to the Effects of
Caerulein Administration
Histology results revealed that the interstitial edema and fibrosis
were more prominent in pancreatic tissues of KCH mice compared to
KC mice (Figure 3C). Also, Western blot results showed that
phospho-Smad3 (a TGF-β effector) and phospho-p65 (the active
form of the p65/p50 NF-κB complex) proteins were more abundant
in pancreata of KCH mice than of KC mice (Figure 5, A and B). In
contrast, there were no differences in total p65, phospho-STAT3, and
phospho-Akt proteins between pancreata of either genotype (Figure 5,
A and B). These results indicate that Prox1 heterozygosis increases
features associated with inflammation in pancreatic tissues expressing
oncogenic Kras. Therefore, we hypothesized that Prox1 heterozygosis
might influence the response of the pancreas to other stressors that
trigger injury and inflammation. We explored this possibility by
comparing the effects of caerulein administration between Ptf1a+/cre
mice and Prox1Δ/+ mice.
Exposure to caerulein increases amylase levels in the blood, causes
acinar cell death, and leads to a transient inflammatory pathology that
is reminiscent of acute-pancreatitis [30]. We injected Ptf1a+/cre mice
and Prox1Δ/+ mice with a single dose of saline or caerulein and
measured serum amylase levels 3 hours post-administration.
Compared with saline, caerulein increased serum amylase levels by
1.7- fold in Ptf1a+/cre mice (P= 0.095) and by 2.8-fold in Prox1Δ/+
mice (P=0.038; Figure 5C). Therefore, the acinar damage inflicted by
Figure 3. Prox1 heterozygosis accelerates early transformation downstream of KrasG12D.A: Small areas of desmoplasia (arrows) are
noticeable in KC and KCH pancreata at 1 month (H&E). These foci include atypical flat epithelial lesions surrounded by abundant stellate
cells (αSMA+) and infiltrating macrophages (F4/80+). Scale bars: 50 μm.B: Quantification of macrophage-positive (F4/80) and total
leukocyte-positive (CD45) areas shows no difference between KC and KCH pancreata at 1 month. In contrast, αSMA+ foci are more
abundant in the KCH specimens.C: (H&E staining) Two-months old KC pancreata have few foci of desmoplasia (arrowheads) harboring
ADMs, and a few PanIN lesions (yellow arrows) surrounded by large portions of normal-looking tissue (arrow). In comparison, 2-month old
KCH pancreata have more numerous PanINs (yellow arrows), more abundant desmoplasia (arrowheads), and less intact acinar tissue
(arrows). Features associated with inflammation (i.e., interstitial edema and fibrosis [trichrome and Sirius red staining]), are more
prominent in KCH pancreata than in KC pancreata at 2 months. Scale bars: 400 μm (H&E), 3 mm (trichrome and Sirius red).D: Quantitative
comparison of the proportion of normal ducts and PanINs between pancreata of 2-month old KC and KCHmice (Ptf1a-Cre).E: (H&E staining)
The pancreata of 4-month old KCHmice that were offspring of Pdx1-Cre (B6C57) breeders displays larger areas of desmoplasia (arrowheads)
and more numerous PanIN lesions (arrows) in comparison to pancreata of KC littermates. Scale bars: 200 μm.F: Quantitative comparison of
theproportionof normal ducts andPanINsbetween pancreata of 4-month old KC and KCHmice (micewereproducedusingPdx1-Cre [B6C57]
breeders).Error bars represent + SEM values from (n=3) individual pancreatic specimens per genotype. *Pb0.05, *** Pb0.001.
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mice. We also compared the recovery of Prox1Δ/+ and Ptf1a+/cre
pancreatic tissues from caerulein administration using histologic and
immunostaining methods. Consistent with the serum amylase results,
various features indicative of inflammation (e.g., edema, and total
leukocyte and macrophage infiltration) were more acute in the
pancreas of Prox1Δ/+ mice 7 days after caerulein administration
(Figure 5, D and E) than in pancreata of similarly treated Ptf1a+/cre
mice. These results demonstrate that Prox1 heterozygosis increasestissue injury and delays recovery from inflammation in pancreatic
tissues exposed to caerulein.
Prox1 Activity Reduces Anchorage-Independent Growth and
Gene Signatures Associated With Cell Transformation, Inva-
siveness and Inflammation, in Pancreatic Cancer Cells
Our results from both mice injected with caerulein and KC mice
indicated that Prox1 activity participates in processes that protect
pancreatic cells from tissue injury and oncogenic transformation. To
Figure 4. Prox1 heterozygosis does not affect pancreatic tumor formation downstream of oncogenic Kras or survival outcome in mice.A:
H&E staining reveals a high-grade IPMN (arrows) in each of KC and KCH pancreata. The IPMNs express CK19 and are surrounded by a
collagen-positive desmoplasia (trichrome staining).B: KC, H&E staining shows the characteristic glandular architecture of a non-invasive
PDAC (the CK19 expression confirms its ductal identity). KCH, An invasive PDAC displays glandular morphology (H&E) and expresses
CK19. The liver metastasis also expresses CK19 and show histologic features of both adenocarcinoma and IPMN. Trichrome staining
reveals abundant collagen deposition around the primary tumors.C: Kaplan-Meier curves show similar survival outcome for KC and KCH
mice (n=16 per genotype).Scale bars: 100 μm (A, B: second, third and fourth columns), 1mm (A, first column and B, first column [except
bottom image that is 3mm]).
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expression in the human pancreatic tumor cell line Capan1 using
retroviral vectors, and compared the morphology, growth and gene
expression profiles between PROX1-Capan1 cells and Capan1 cells
infected with control viruses. Morphologic analyses using bright
microscopy revealed membranous extensions resembling filopodia in
most control-Capan1 cells (Figure 6A). In contrast, PROX1-Capan1
cells had very small filopodia or completely lacked these structures
(Figure 6A). Also, staining for F-actin showed prominent distribution of
filamentous actin at the leading edge in control-Capan1 cells and more
compact distribution in peripheral PROX1-Capan1 cells (Figure 6B).
Furthermore, staining with E-cadherin antibodies showed that this
protein was restricted to cells located in the center in control-Capan1
cultures, whereas most cells in the PROX1-Capan1 cultures strongly
expressed E-cadherin (Figure 6C). These results demonstrate that
PROX1 activity reduces morphologic traits associated with cell
adhesion and migration in pancreatic tumor cells.
Takahashi et al [17] showed that PROX1 ectopic expression
decreases growth in MiaPaCa2 cells. Similarly, using an ATP-based
viability assay we uncovered that ectopic PROX1 expression reduced
the expansion of Capan1 cells (Figure 6D). Furthermore, colony agar
formation assay results showed that Capan1 cells that expressed
PROX1 had significantly lower anchorage-independent growth in
comparison to control Capan1 cells (Figure 6E). These results further
prove that Prox1 activity reduces the malignant potential of
transformed pancreatic cells. To gain mechanistic insight into this
effect of Prox1 function, the gene expression profiles of PROX1-Ca-
pan1 cells and control-Capan1 cells were compared using Affymetrix
arrays. This analysis uncovered N2-fold significant upregulation of
216 genes, and N2-fold significant downregulation of 480 genes, in
PROX1-Capan1 cells compared to control-Capan1 cells (Figure 5F).
Results of gene ontology analysis showed significant enrichment of
epithelial development and regulation of cell proliferation pathways
within the genes that were upregulated in PROX1-Capan1 cells
(Supplemental Table 4). QRT-PCR results confirmed the upregu-
lation of some of these genes in Capan1 cells virally transduced withPROX1 (Supplemental Figure 4), but the reciprocal effect was not
observed in pancreatic tissues from KCH mice (data not shown).
Therefore, we conclude that Prox1 increased the former genes in
cooperation with factors that are specific to Capan1 cells.
Both gene ontology and qRT-PCR results revealed that functions
involving wound healing, chemotaxis, cell adhesion, cell motility, and
inflammation (Figures 6F and 7A, and Supplemental Table 4) were
significantly downregulated in PROX1-Capan1 cells. QRT-PCR
analysis of various candidates selected from the PROX1-Capan1–
downregulated data sets showed that proinflammatory transcripts
(Reg3b, Saa1, Nfkbiz, Il-6, Cxcl2, Cxcl3, Ccl5, Il1rl1), transcripts that
promote tumor invasiveness (Mmp9, Mmp1, Plat, Plau, Plaur), and
transcripts associated with pancreatic neoplastic transformation
(S100a9, Cd44, Cldn2, Cldn18), were substantially increased in KC
pancreata compared to Ptf1a+/cre (control) pancreata (Figure 7B).
More remarkably, results from similar analyses revealed that
numerous transcripts involved with functions that were downregu-
lated in PROX1-Capan1 cells, had significantly higher expression in
KCH pancreata compared to KC pancreata (Figure 7B) at 1 month of
age. Likewise, we found that the ADMs from KCH mice expressed
considerably higher levels of the proinflammatory transcripts Il-6,
Saa1 and Cxcl3; the tumor invasiveness-related transcripts Mmp9,
Plau, Plaur and Plat; and the PanIN-specific transcript Cldn18
(Figures 2D and 7C), in comparison to ADMs from KC mice. These
results establish that Prox1 activity suppresses pathways that confer
invasiveness and pathways involved with inflammation in trans-
formed pancreatic cells.
Discussion
Acinar plasticity manifests in response to injury or stress to help repair
the damaged tissue and to facilitate regeneration. In rodents (and
probably also in humans) afflicted with pancreatitis the acinar cells
transiently de-differentiate and undergo ADM conversion, a process
that reverts once the damage and inflammation subside. However,
under pathologic conditions associated with sustained inflammation
or oncogenic stress this course is derailed and the progression of
Figure 5. Prox1 heterozygosis accentuates tissue damage and inflammation triggered by caerulein or KrasG12D.A, B: Western blot (A) and
densitometry analysis (B) showing expression of markers associated with inflammation and transformation downstream of KrasG12D
activity. β actin served as loading control. Phospho-p65 and phospho-Stat3 values were calculated relative to their total levels whereas the
rest of the proteins were calculated relative to β actin. The pancreatic tissues were harvested at 3 months of age.C: Serum amylase
increases more in Prox1 /+ mice than in Ptf1a+/cre mice 3 hours after a single injection of caerulein (72 μg/kg body weight).D: Infiltrates of
both macrophage (F4/80-immunopositive) and total leukocytes (CD45-immunopositive) are more abundant in Prox1 /+ pancreata than in
Ptf1a+/cre pancreata, 7 days post-caerulein administration.E: Prox1 /+ pancreata have more prominent interstitial edema (H&E staining)
and more immune infiltrates (i.e., F4/80+cells and CD45+ cells, arrows) than Ptf1a+/cre pancreata 7 days post-caerulein injection. Prox1 /+
pancreata injected with saline have normal morphology and do not display features of inflammation (scale bars: 200 μm).Error bars
represent + SEM values from ((n=3 [B], n=4 [C, saline], n=6 [C, caerulein], and n=3 (D)] specimens per genotype. *Pb0.05.
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ADMs is accompanied by reactivation of a “progenitor signature”
involving TFs and signaling pathways that normally are expressed in
embryonic pancreatic precursors [5,6,34]. Our study uncovered that
Prox1 is a novel component of the previous “progenitor signature”, and
revealed that its function limits the development of ADMs and the
formation of pancreatic neoplasias in the setting of oncogenic Kras.
Although currently we do not know the functional outcome of
Prox1 induction in wild-type ADMs, we hypothesize that this step
could help to disassemble the program of acinar differentiation
because we previously showed that Prox1 activity opposes acinar
development in pancreatic progenitors [13]. Moreover, Prox1
induction could help conferring “progenitor/ductal” characteristics
to ADMs as we previously described that Prox1 activity is necessary
for ductal development [14]. This potential role of Prox1 would be
similar to that proposed for Hnf6, a TF though to function in thesame pathway as Prox1 in pancreatic ductal cells [14–16] and whose
induction in ADMs was shown to decrease acinar gene expression [8].
Further studies should clarify the functional significance of Prox1
expression in non-transformed ADMs.
While Prox1 induction probably assists the initial steps of ADMs
conversion, we found that its activity also posses a barrier for the
progression of ADMs into neoplasias in the context of oncogenic
Kras. This latter function may be due both to indirect effects on the
microenvironment (discussed below) and to cell autonomous effects
on epithelial character. Not only did loss of one Prox1 allele result in
greater numbers of early neoplastic lesions in vivo, it also led to
elevated expression of Cldn18 in isolated acini that were induced to
undergo ADM in vitro. Claudin-18 is one of few markers that
distinguish ADMs from early neoplastic lesions. Thus, reduction of
Prox1 enables transition from benign to neoplastic disease in the
models shown here.
Figure 6. PROX1 ectopic expression decreases the transforming potential of Capan1 cells.A: Nomarski images of cells counterstained
with hematoxylin show conspicuous cell protrusions (arrows) in Capan1-puro cells but not in Capan1-PROX1 cells. Scale bars: 40 μm.B,
C: Co-staining for F-actin/Prox1 (B) and F-actin/E-cadherin (C) depicts focal and cell-cell adhesions in Capan1-PROX1 cells and
Capan1-puro cells (arrows indicate cell protrusions and arrowheads adherent junctions). Scale bars: 40 μm.D: Capan1-PROX1 cells
display reduced expansion in comparison to Capan1 cells and Capan1-puro cells. Data were generated from 3 individual cultures.E:
Capan1-PROX1 cells produced significantly fewer colonies in soft agar assays compared to Capan1-puro cells. Data were generated from
2 independent experiments, each in triplicate (error bars =mean± SD). *Pb0.05, **Pb0.01.F: Results of Gene Ontology analysis showed
that 216 genes were upregulated N 2-fold and 480 genes were downregulated N 2-fold, in Capan1-PROX1 cells vs. Capan1-puro cells.
Functions associated with epithelium development and cell proliferation were enriched in the upregulated genes, and functions
associated with inflammation, wound healing, cellular motion and cell adhesion were enriched in the downregulated genes.
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pathways leading to cell cycle arrest or senescence in ADMs that
express KrasG12D, since we found that KCH acini produced larger
and more proliferative cysts than KC acini. A similar role for Prox1
was proposed in the developing lens where its loss of function caused
abnormal cell proliferation and downregulation of the cell-cycle
inhibitors p57 and p27 [35]. Moreover, a recent study showed that in
lens epithelial cells expressing H-rasG12V, Prox1 expression was
upregulated together with p57 and p27 [36]. This potential negative
effect of Prox1 activity for KrasG12D-induced transformation would
explain why this TF is downregulated in early neoplasias. Therefore,
one could envision that in acini undergoing metaplastic conversion
Prox1 is initially induced to help establishing a “progenitor/ductal
state”, but as the Kras-induced oncogenic program process advances
loss of Prox1 expression enables progression from ADM to PanIN.
Our future efforts should attempt to identify the mechanism(s)
responsible for silencing Prox1 expression in PanINs. In this regards,
it is intriguing that Prox1 transient expression in ADMs is identical tothat of Hnf6 because other studies concluded that Hnf6 might act
upstream of Prox1 in pancreatic tissues [8,15,16].
Another important effect of Prox1 heterozygosis is that this
condition increased the focal areas of desmoplasia, the number of
preneoplasias, and features of inflammation, in the pancreata of
young KC mice. These alterations could result from enhanced
expression of proinflammatory proteins (e.g., Il-6, encoding a potent
activator of pancreatic stellate cells [37], metalloproteases, plasmin-
ogen activators, and other proteins known to participate in neoplastic
transformation and tissue repair [38–41] in ADMs that carry reduced
Prox1 dosage. In addition, Prox1 heterozygosis could have influenced
the transformation of acinar cells in a non-cell autonomous manner
by increasing the production of proinflammatory and other
tumor-promoting factors in ductal cells. The notion that Prox1
regulates similar processes in transformed ADMs and in pancreatic
ductal cells is intriguing because Prox1 is continuously expressed in
the pancreatic ducts and these structures are highly refractory to
KrasG12D–induced transformation [7]. Future studies using
Figure 7. Prox1-heterozygosis increases the expression of transcripts encoding proteins associated with inflammation and
transformation in KrasG12D-pancreatic tissues.A: Quantitative PCR confirms expression changes in Capan1-PROX1 cells of
downregulated genes selected from the pathway enrichment analyses.B: Quantitative PCR shows higher expression of several
transcripts identified in the Capan1-PROX1 microarray, in pancreata of 1-month old KCHmice in comparison to those tissues of Ptf1a+/cre
(control) or KC mice (asterisks compare KC versus KCH results).C: Quantitative PCR results show variable expression of transcripts
selected from the Capan1-PROX1 expression analysis, in acinar cultures prepared from KC and KCH pancreata. Acini from KC and KCH
pancreata show similar changes in the transcription of Amylase (down) and Ck19 (up) after 3 days in culture. Prox1 transcripts show
marked upregulation in KC acinar cultures but not in KCH cultures between days 0 and 3. Plau, Plat, Plaur, Mmp9, Saa1, Cxcl3 and Il-6
transcripts show higher upregulation in KCH tissues compared to KC tissues during the culture period.Error bars represent + SEM values
from: (n=3) independent viral transduction experiments in Capan1-PROX1 cells and Capan1-puro cells (A), (n=4-6) individual pancreatic
tissues (B), and (n=3-4) individual cultures per time point (C).*Pb0.05, **Pb0.01 and ***Pb0.001.
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affects the susceptibility of acinar and ductal cells to oncogenic
transformation.
Inflammation plays a key role in pancreatic repair by eliminating
injured cells and promoting epithelial renewal [42,43]. However,
inflammation also contributes to various important aspects of
pancreatic tumorigenesis such as: facilitating ADM and PanIN
formation [44,45], inducing epithelial-to-mesenchymal transition at
the PanIN stage [46], promoting desmoplasia [43,47], and
amplifying Kras activity to pathologic levels [48]. The strong reliance
of KrasG12D-driven transformation on inflammatory stimuli explains
why pathologic conditions such as chronic pancreatitis increase the
risk for pancreatic cancer [49]. We found that Prox1 heterozygosis
enhanced several features associated with inflammation in a mouse
model of pancreatic cancer induced by oncogenic Kras (e.g.,
desmoplasia, fibrosis, and expression of phospho-Smad3 and
phospho-p65 proteins) and in a mouse model of caerulein-induced
pancreatitis (e.g., persistence of immune infiltrates). Furthermore,
Prox1 could directly repress inflammatory pathways in pancreatic
cells because we identified Prox1-binding sites in regulatory regions of
various NF-κB target genes (data not shown). Our future efforts willtry to identify the mechanisms downstream of Prox1 activity
responsible for protection from excessive injury and attenuation of
inflammatory responses in the pancreas. This information should
have therapeutic relevance because it could identify processes or
factors that could be targeted at the early stages of the neoplastic
process. Furthermore, our study predicts that the effects of
pancreatitis or oncogenic transformation are more severe in
individuals carrying reduced dosage of PROX1 in the pancreas.
Another major conclusion of our study is that Prox1 activity does
not seem to play a role in pancreatic tumor formation but rather in
the initiation of the process. In fact, similar to the report of the
Takahashi lab [17], we determined that Prox1 expression is negligible
or completely absent in neoplasias and tumors in the pancreas of mice
and humans. Moreover, although in a few human PDAC specimens
we detected moderate-to-low PROX1 protein expression, our results
of in silico analyses of published databases did not reveal significant
correlation between PROX1 expression levels and the differentiation
status of pancreatic tumors or patient survival (data not shown). It
remains to be determined whether PROX1 is functionally inactive in
tumors that express this protein or if certain PDAC mutations offset
the activity of this transcription factor (e.g., like those described by
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PROX1 ectopic expression lessens the transforming potential of
pancreatic cancer cells. Identifying the specific effectors downstream
of Prox1 activity that reduce invasiveness and traits associated with
transformation in pancreatic tumor cells could open new therapeutic
opportunities and help restraining the metastatic potential of this
devastating form of cancer.
In summary, we discovered that Prox1 heterozygosis sensitizes the
pancreas to excessive damage and inflammation caused by injury or
oncogenic stress. Our findings predict that dissecting the mecha-
nism(s) behind this novel role of Prox1 should help the diagnosis and
treatment of some pathologic conditions that predispose to pancreatic
cancer in humans.
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